Oculis Holding AG (OCS)
(Delayed Data from NSDQ)
$11.93 USD
+0.04 (0.29%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.95 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Oculis Holding AG [OCS]
Reports for Purchase
Showing records 1 - 20 ( 27 total )
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
OCS-02 Phase 2b DED Trial Reports Positive Results; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Restoret Unlikely to Compete Against OCS-01 in DME; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Financing Completed; Dry Eye Data Approaching; Reiterate Buy; Modulating PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Analyst Day Highlights Opportunity for OCS-01 OCS-02,Outlines Key Catalysts
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Second Pivotal Trial in DME Initiated; DED Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Second Pivotal Trial in Ocular Inflammation and Pain Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Stage 2 of Phase 3 DIAMOND-1 Trial in DME Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Phase 2b Trial in Dry Eye Disease Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Q3: Pipeline Progress Ahead of Multiple Catalysts in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
3Q23 Financial Results; Three Pivotal Trials Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
2Q23 and 1H23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Q2:23 H1:23: Focused on Advancing the Pipeline in H2:23,Readouts in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
OCS-01 Phase 3 Trial Meets Primary Endpoints; Raising PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Positive Topline Ph3 OPTIMIZE Results for OCS-01; NDA Submission in Late ''24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Cystoid Macular Edema Trial Starts Patient Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Oculis Holding AG
Industry: Medical - Biomedical and Genetics
Retina RD Day Sets the Stage for Upcoming CME & AON Catalysts in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A